Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Chief Development Officer | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-05-11 | Direct | 66,000 |
Reported balance
After 2026-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 66,000 · Balance 66,000 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.28 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Disposition to issuer · Disposed 66,000 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2033-02-14 | Direct | 57,950 |
Reported balance
After 2026-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-19 · Grant · Acquired 57,950 · Balance 57,950 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.29 · Expires 2033-02-14 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-19 · Disposition to issuer · Disposed 57,950 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2031-04-29 | Direct | 41,665 |
Reported balance
After 2026-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-19 · Grant · Acquired 41,665 · Balance 41,665 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2031-04-29 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-19 · Disposition to issuer · Disposed 41,665 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
F2: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.
F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
F5: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 23:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 41,665 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 6 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,665 shares Expires 2031-04-29 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 41,665 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 5 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,665 Underlying: Common Stock · 41,665 shares Expires 2031-04-29 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 57,950 | Not disclosed Strike: $14.29 | Not disclosed |
DisclosureSEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 4 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,950 shares Expires 2033-02-14 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 57,950 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 3 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,950 Underlying: Common Stock · 57,950 shares Expires 2033-02-14 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 66,000 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 2 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,000 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:16 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 66,000 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120235 · ownership.xml · derivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:35 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064141 · ownership.xml · derivative · entry 2 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-02-19 F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:35 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-064141 · ownership.xml · nonDerivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,823 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. F2 · balance_after: Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 01:13 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 5,956 | $1.01 | $6,027.47 |
DisclosureSEC source: 0001193125-26-006765 · ownership.xml · nonDerivative · entry 2 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,823 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2 · balance_after: Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 01:13 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 3,295 | $1.00 | $3,304.89 |
DisclosureSEC source: 0001193125-26-006765 · ownership.xml · nonDerivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,779 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. F2 · balance_after: Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. F3 · balance_after: Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 100,500 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000950170-25-030057 · ownership.xml · derivative · entry 2 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 100,500 shares Expires 2035-02-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 50,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-030057 · ownership.xml · nonDerivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,074 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. Read SEC document |
| January 03, 2025 Filed Jan 8, 2025 01:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,957 | $1.34 | $3,965.34 |
DisclosureSEC source: 0000950170-25-003157 · ownership.xml · nonDerivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,824 F1 · shares: Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025. F2 · balance_after: Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. F3 · balance_after: Includes 2,224 shares purchased on March 31, 2024 under the Issuer's Employee Stock Purchase Plan ("ESPP") and 2,322 shares purchased on September 30, 2024 under ESPP in transactions exempt from reporting under Section 16(b)3. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000166 · form4.xml · derivative · entry 2 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-03-14 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000166 · form4.xml · nonDerivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,235 F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Reflects the adjusted total which includes the purchase of 735 shares under the AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan on September 29, 2023. Read SEC document |
| March 15, 2024 Filed Mar 29, 2024 20:16 UTC Amendment | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000192 · form4.xml · nonDerivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,235 F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:28 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 57,950 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0000899243-23-005557 · doc4.xml · derivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,950 Underlying: Common Stock · 57,950 shares Expires 2033-02-14 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:32 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018296 · doc4.xml · derivative · entry 1 Chanda Sanjay · CIK 0001571820 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.